Patient characteristics
| Clinical characteristics . | Group 1: Patients receiving HBsAg-positive marrow (n = 18) . | Group 2: Patients receiving HBsAg-negative marrow (n = 18) . |
|---|---|---|
| Male/female | 15/3 | 15/3 |
| Median age, y (range) | 28 (13-45) | 34 (17-47) |
| Hepatitis serology | ||
| HBsAg positive | 9 | 9 |
| HBeAg positive/HBeAb positive | 2/7 | 5/4 |
| HBV DNA positive by bDNA assay, mEq/mL (median, range) | 4 (1400, 900-2000) | 5 (1200, 700-2200) |
| HBV DNA positive by PCR | 8 | 7 |
| HBsAb positive, titer in mIU/mL (median, range) | 6 (1300, 100-2800) | 4 (1800, 200-2400) |
| HBsAg, HBsAg, and HBcAb negative | 3 | 5 |
| Precore A1896 variants alone present | 2 | 1 |
| Core promoter T1762/A1764 variant alone present | 1 | 1 |
| Both A1896 and T1762/A1764variants present | 2 | 1 |
| Underlying disease | ||
| AML or MDS/ALL/CML/NHL/MM | 7/3/6/1/1 | 7/3/6/1/1 |
| Preconditioning regimen | ||
| Cy-TBI/Bu-Cy-TBI/VP16-Cy-TBI/Mel-TBI/Bu-Cy | 4/7/3/1/3 | 6/5/1/1/5 |
| GVHD prophylaxis | ||
| Short MTX + CSP/CSP alone | 17/1 | 17/1 |
| History of retransplant hepatitis | 6 | 3 |
| Donor HBV status | ||
| HBsAg positive | 18 | 0 |
| HBeAg positive/HBeAb positive | 5/13 | 0/0 |
| HBV DNA positive by bDNA assay | 6 | 0 |
| HBV DNA positive by PCR | 12 | 2 |
| HBsAb positive, titer in IU/mL (median, range) | 0 | 9 (900, 80-3000) |
| HBcAb positive | 0 | 4 |
| HBsAg, HBsAb, and HBcAb negative | 0 | 9 |
| Precore A1896variant alone present | 2 | 1 |
| Core promoter T1762/A1764 variant alone present | 1 | 0 |
| Both A1764 and A1896/T1762 variants present | 2 | 0 |
| Clinical characteristics . | Group 1: Patients receiving HBsAg-positive marrow (n = 18) . | Group 2: Patients receiving HBsAg-negative marrow (n = 18) . |
|---|---|---|
| Male/female | 15/3 | 15/3 |
| Median age, y (range) | 28 (13-45) | 34 (17-47) |
| Hepatitis serology | ||
| HBsAg positive | 9 | 9 |
| HBeAg positive/HBeAb positive | 2/7 | 5/4 |
| HBV DNA positive by bDNA assay, mEq/mL (median, range) | 4 (1400, 900-2000) | 5 (1200, 700-2200) |
| HBV DNA positive by PCR | 8 | 7 |
| HBsAb positive, titer in mIU/mL (median, range) | 6 (1300, 100-2800) | 4 (1800, 200-2400) |
| HBsAg, HBsAg, and HBcAb negative | 3 | 5 |
| Precore A1896 variants alone present | 2 | 1 |
| Core promoter T1762/A1764 variant alone present | 1 | 1 |
| Both A1896 and T1762/A1764variants present | 2 | 1 |
| Underlying disease | ||
| AML or MDS/ALL/CML/NHL/MM | 7/3/6/1/1 | 7/3/6/1/1 |
| Preconditioning regimen | ||
| Cy-TBI/Bu-Cy-TBI/VP16-Cy-TBI/Mel-TBI/Bu-Cy | 4/7/3/1/3 | 6/5/1/1/5 |
| GVHD prophylaxis | ||
| Short MTX + CSP/CSP alone | 17/1 | 17/1 |
| History of retransplant hepatitis | 6 | 3 |
| Donor HBV status | ||
| HBsAg positive | 18 | 0 |
| HBeAg positive/HBeAb positive | 5/13 | 0/0 |
| HBV DNA positive by bDNA assay | 6 | 0 |
| HBV DNA positive by PCR | 12 | 2 |
| HBsAb positive, titer in IU/mL (median, range) | 0 | 9 (900, 80-3000) |
| HBcAb positive | 0 | 4 |
| HBsAg, HBsAb, and HBcAb negative | 0 | 9 |
| Precore A1896variant alone present | 2 | 1 |
| Core promoter T1762/A1764 variant alone present | 1 | 0 |
| Both A1764 and A1896/T1762 variants present | 2 | 0 |
HBsAg indicates hepatitis B surface antigen; HBsAb, hepatitis B surface antibody; HBeAg, hepatitis e antigen; HBeAb, hepatitis e antibody; HBV, hepatitis B virus; bDNA, branched DNA; PCR, polymerase chain reaction; Bu, busulphan; Cy, cyclophosphamide; TBI, total body irradiation; VP16, etoposide; Mel, melphalan; GVHD, graft-versus-host disease; MTX, methotrexate; CSP, cyclosporin; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HBcAb, hepatitis B core antibody.